Antimicrobial susceptibilities of Enterobacteriaceae in community-acquired urinary tract infections during a 5-year period: A single hospital study in Korea

Infection and Chemotherapy

Volumn 49, Issue 3, 2017, Pages 184-193

  Park, Jin Ju ^a   Seo, Yu Bin ^a   Lee, Jacob ^a  

^a Hallym University College of Medicine   (South Korea)

Author keywords

Community acquired infection; Extended spectrum lactamase; Susceptibility; Urinary tract infections

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CITROBACTER; COMMUNITY ACQUIRED INFECTION; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCUS; ENZYME SYNTHESIS; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NONHUMAN; PROTEUS; PSEUDOMONAS; RETROSPECTIVE STUDY; SERRACIA MARCESCENS; SOUTH KOREA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS SAPROPHYTICUS; STREPTOCOCCUS; TREND STUDY; URINARY TRACT INFECTION; URINE CULTURE;

EID: 85030170661     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2017.49.3.184     Document Type: Article

References (32)

1. Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, Pérez-Cano R, Pascual A. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-94
2. Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, Senger SS. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010;16:147-51
3. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52-9
4. Rodríguez-Baño J, Navarro M. Extended-spectrum β-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect 2008;14 (Suppl 1):104-10
5. Kim B, Kim J, Seo MR, Wie SH, Cho YK, Lim SK, Lee JS, Kwon KT, Lee H, Cheong HJ, Park DW, Ryu SY, Chung MH, Ki M, Pai H. Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection 2013;41:603-12
6. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20
7. Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014. Diagn Microbiol Infect Dis 2016;85:459-65
8. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791-7
9. Park SH, Choi SM, Lee DG, Kim J, Choi JH, Kim SH, Kwon JC, Yoo JH. Emergence of extended-spectrum beta-lact amase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes. Microb Drug Resist 2011;17:537-44
10. Burgmann H, Stoiser B, Heinz G, Schenk P, Apfalter P, Zedtwitz-Liebenstein K, Frass M, Carmeli Y. Likelihood of inadequate treatment: a novel approach to evaluating drug-resistance patterns. Infect Control Hosp Epidemiol 2009;30:672-7
11. Davis ME, Anderson DJ, Sharpe M, Chen LF, Drew RH. Constructing unit-specific empiric treatment guidelines for catheter-related and primary bacteremia by determining the likelihood of inadequate therapy. Infect Control Hosp Epidemiol 2012;33:416-20
12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 24th informational supplement. Wayne, PA: CLSI; 2014;M100-S24
13. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 21st informational supplement. Wayne, PA: CLSI; 2011;M100-S21
14. Rodriguez-Baño J, Paterson DL. A change in the epidemiology of infections due to extended-spectrum β-lactamase-producing organisms. Clin Infect Dis 2006;42:935-7
15. The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection and Inflammation, The Korean Society of Clinical Microbiology. Clinical guideline for the diagnosis and treatment of urinary tract infections: asymptomatic bacteriuria, uncomplicated & complicated urinary tract infections, bacterial prostatitis. Infect Chemother 2011;43:1-25
16. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000;46:669-83
17. Yilmaz E, Akalin H, özbey S, Kordan Y, Sinirtas M, Gürcüoglu E, özakin C, Heper Y, Mistik R, Helvaci S. Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother 2008;20:581-5
18. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C, Almela M, Almirante B, Grill F, Colomina J, Giménez M, Oliver A, Horcajada JP, Navarro G, Coloma A, Pascual A; Spanish Network for Research in Infectious Diseases (REIPI). Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010;50:40-8
19. Gopal Rao G, Batura D, Batura N, Nielsen PB. Key demographic characteristics of patients with bacteriuria due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in a multiethnic community, in North West London. Infect Dis (Lond) 2015;47:719-24
20. Søraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae-a case-control study in a low prevalence country. PLoS One 2013;8:e69581
21. Frakking FN, Rottier WC, Dorigo-Zetsma JW, van Hattem JM, van Hees BC, Kluytmans JA, Lutgens SP, Prins JM, Thijsen SF, Verbon A, Vlaminckx BJ, Cohen Stuart JW, Leverstein-van Hall MA, Bonten MJ. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum β-lactamase producing bacteria. Antimicrob Agents Chemother 2013:57;3092-9
22. Gradel KO, Jensen US, Schønheyder HC, Østergaard C, Knudsen JD, Wehberg S, Søgaard M; Danish Collaborative Bacteraemia Network (DACOBAN). Impact of appropriate empirical antibiotic treatment on recurrence and mortality in patients with bacteraemia: a population-based cohort study. BMC Infect Dis 2017;17:122
23. Esparcia A, Artero A, Eiros JM, Balaguer M, Madrazo M, Alberola J, Nogueira JM. Influence of inadequate antimicrobial therapy on prognosis in elderly patients with severe urinary tract infections. Eur J Intern Med 2014;25:523-7
24. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH. Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 2011;39:46-51
25. Harris PN, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 2015;15:475-85
26. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual á; Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167-74
27. Trivedi M, Patel V, Soman R, Rodriguez C, Singhal T. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials. J Assoc Physicians India 2012;60:28-30
28. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012;67:2793-803
29. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis 2013;17:e159-63
30. Park SH, Choi SM, Chang YK, Lee DG, Cho SY, Lee HJ, Choi JH, Yoo JH. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 2014;69:2848-56
31. Seo YB, Kim YK, Lee J, Song W. Use of non-carbapenem antibiotics in patients with urinary tract infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Korean J Healthc Assoc Infect Control Prev 2016;21:50-6
32. Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol 2015;47:1059-66